[go: up one dir, main page]

ATE556080T1 - Purinderivat - Google Patents

Purinderivat

Info

Publication number
ATE556080T1
ATE556080T1 AT05743186T AT05743186T ATE556080T1 AT E556080 T1 ATE556080 T1 AT E556080T1 AT 05743186 T AT05743186 T AT 05743186T AT 05743186 T AT05743186 T AT 05743186T AT E556080 T1 ATE556080 T1 AT E556080T1
Authority
AT
Austria
Prior art keywords
purine derivative
purine
derivative
Prior art date
Application number
AT05743186T
Other languages
English (en)
Inventor
Philip Blatcher
Richard Peter Charles Cousins
Derek Norman Evans
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0411563A external-priority patent/GB0411563D0/en
Priority claimed from GB0509521A external-priority patent/GB0509521D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of ATE556080T1 publication Critical patent/ATE556080T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
AT05743186T 2004-05-24 2005-05-23 Purinderivat ATE556080T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0411563A GB0411563D0 (en) 2004-05-24 2004-05-24 Compounds
GB0509521A GB0509521D0 (en) 2005-05-10 2005-05-10 Compounds
PCT/EP2005/005651 WO2005116037A1 (en) 2004-05-24 2005-05-23 Purine derivative

Publications (1)

Publication Number Publication Date
ATE556080T1 true ATE556080T1 (de) 2012-05-15

Family

ID=34968031

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05743186T ATE556080T1 (de) 2004-05-24 2005-05-23 Purinderivat

Country Status (16)

Country Link
US (1) US7737126B2 (de)
EP (1) EP1756120B1 (de)
JP (1) JP5007225B2 (de)
AR (1) AR049384A1 (de)
AT (1) ATE556080T1 (de)
AU (1) AU2005247601A1 (de)
BR (1) BRPI0511424A (de)
CA (1) CA2566863A1 (de)
ES (1) ES2383604T3 (de)
IL (1) IL179009A0 (de)
MA (1) MA28611B1 (de)
MX (1) MXPA06013627A (de)
NO (1) NO20065757L (de)
PE (1) PE20060272A1 (de)
RU (1) RU2006141276A (de)
WO (1) WO2005116037A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT200500281A (es) 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0500785D0 (en) 2005-01-14 2005-02-23 Novartis Ag Organic compounds
GB0514809D0 (en) * 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
GB0523778D0 (en) * 2005-11-23 2006-01-04 Glaxo Group Ltd Novel method
GB0523845D0 (en) * 2005-11-23 2006-01-04 Glaxo Group Ltd Novel salts
EP1953139A4 (de) * 2005-11-25 2010-07-28 San Apro Ltd Verfahren zur herstellung von fluoriertem sulfoniumalkylfluorphosphat
AR058109A1 (es) 2005-12-20 2008-01-23 Glaxo Group Ltd Acido 3 - (4 - {[4 -(4 -{[3 - (3, 3 - dimetil - 1 - piperidinil)propil]oxi}fenil) - 1 - piperidinil]carbonil} - 1 - naftalenil)propanoico como antagonistas de los receptotres de histamina h1/h3, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamie
RU2457209C2 (ru) 2006-04-21 2012-07-27 Новартис Аг Производные пурина, предназначенные для применения в качестве агонистов аденозинового рецептора а2а
GB0607950D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0611587D0 (en) 2006-06-12 2006-07-19 Glaxo Group Ltd Novel compounds
EP1889846A1 (de) 2006-07-13 2008-02-20 Novartis AG Purinderivate als A2a Agonisten
EP1903044A1 (de) 2006-09-14 2008-03-26 Novartis AG Adenosinderivate als Agonisten des A2A-Rezeptors
WO2008055874A1 (en) * 2006-11-10 2008-05-15 Novartis Ag Cyclopentene diol monoacetate derivatives

Family Cites Families (204)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3796700A (en) 1970-06-30 1974-03-12 Takedo Chem Ind Ltd Adenosine derivatives and the production thereof
DE2034785A1 (de) 1970-07-14 1972-01-20 Boehnnger Mannheim GmbH, 6800 Mann heim Waldhof Adenosin 5 carbonsäurederivate
CA1019727A (en) 1971-03-18 1977-10-25 Abbott Laboratories Adenosine-5'-carboxylic acid amides
BE789773A (fr) 1971-10-08 1973-04-06 Schering Ag Adenosines n6 -substituees et leur procede de
US3864483A (en) 1972-03-22 1975-02-04 Abbott Lab Adenosine-5{40 -carboxylic acid amides
CA1082695A (en) 1972-04-10 1980-07-29 Francis E. Fischer Process for preparing adenosine-5'-carboxamides
US3966917A (en) 1974-07-30 1976-06-29 Abbott Laboratories Platelet aggregation inhibitors
DE2621470A1 (de) 1976-05-14 1977-12-01 Pharma Waldhof Gmbh & Co Nucleosidcarbonsaeurenitrile und ihre derivate, und verfahren zu ihrer herstellung
US4167565A (en) 1976-11-08 1979-09-11 Abbott Laboratories Adenosine-5'-carboxamides and method of use
AU8379182A (en) 1981-06-04 1982-12-09 Procter & Gamble Company, The Composition of salicylates and purine derivatives
CA1239397A (en) 1983-08-01 1988-07-19 James A. Bristol N.sup.6-substituted adenosines
DE3406533A1 (de) 1984-02-23 1985-08-29 Boehringer Mannheim Gmbh, 6800 Mannheim Verwendung von adenosin-derivaten als antiallergica und arzneimittel, die diese enthalten
AU582359B2 (en) 1984-04-18 1989-03-23 Nelson Research & Development Company N-6 substituted adenosine derivatives as cardiac vasodilators
US5310731A (en) 1984-06-28 1994-05-10 Whitby Research, Inc. N-6 substituted-5'-(N-substitutedcarboxamido)adenosines as cardiac vasodilators and antihypertensive agents
US4663313A (en) 1984-10-26 1987-05-05 Warner-Lambert Company N6 -tricyclic adenosines for treating hypertension
AU575438B2 (en) 1984-10-26 1988-07-28 Warner-Lambert Company N6 - substituted deoxyribose analogues of adenosines
CA1254888A (en) 1984-10-26 1989-05-30 Bharat Trivedi N.sup.6-bicycloadenosines
US4738954A (en) 1985-11-06 1988-04-19 Warner-Lambert Company Novel N6 -substituted-5'-oxidized adenosine analogs
US4755594A (en) 1986-01-31 1988-07-05 Warner-Lambert Company N6 -substituted adenosines
US5106837A (en) 1988-03-16 1992-04-21 The Scripps Research Institute Adenosine derivatives with therapeutic activity
JPH0696534B2 (ja) 1986-04-25 1994-11-30 ヘキストジヤパン株式会社 抗痴呆剤
US4767747A (en) 1986-08-28 1988-08-30 Warner-Lambert Company Method for treating congestive heart failure with N6 -acenaphthyl adenosine
WO1988003147A1 (en) 1986-10-31 1988-05-05 Warner-Lambert Company Selected n6-substituted adenosines having selective a2 binding activity
AU8274187A (en) 1986-10-31 1988-05-25 Warner-Lambert Company Heteroaromatic derivatives of adenosine
NL8702926A (nl) 1986-12-15 1988-07-01 Sandoz Ag Nieuwe furanuronzuurderivaten en werkwijzen voor het bereiden en toepassen van deze derivaten.
US4968697A (en) 1987-02-04 1990-11-06 Ciba-Geigy Corporation 2-substituted adenosine 5'-carboxamides as antihypertensive agents
EP0277917A3 (de) 1987-02-04 1990-03-28 Ciba-Geigy Ag Bestimmte Derivate von Adenosin-5'-carboxamid
US4962194A (en) 1987-04-02 1990-10-09 Warner-Lambert Company Method of preparing 51,N6-disubstituted adenosines from inosines
LU87181A1 (fr) 1987-04-06 1988-11-17 Sandoz Sa Nouveaux derives de l'acide furannuronique,leur preparation et leur utilisation comme medicaments
US5219840A (en) 1987-04-06 1993-06-15 Sandoz Ltd. Antihypertensive 9-(2,N6 -disubstituted adenyl) ribofuranuronic acid derivatives
JPH0725785B2 (ja) 1989-01-11 1995-03-22 日本臓器製薬株式会社 アデノシン誘導体及び該化合物を有効成分として含有する医薬組成物
US5646128A (en) 1989-09-15 1997-07-08 Gensia, Inc. Methods for treating adenosine kinase related conditions
IE903747A1 (en) 1989-10-19 1991-04-24 Searle & Co Method of treating gastrointestinal motility disorders
US5055569A (en) 1989-10-19 1991-10-08 G. D. Searle & Co. N-(6)-substituted adenosine compounds
JP2580091B2 (ja) 1990-01-11 1997-02-12 アイシス・ファーマシューティカルス・インコーポレーテッド Ｒｎａ活性および遺伝子発現を検出および変調するための組成物および方法
US5140015A (en) 1990-02-20 1992-08-18 Whitby Research, Inc. 2-aralkoxy and 2-alkoxy adenosine derivatives as coronary vasodilators and antihypertensive agents
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
US5280015A (en) 1990-09-05 1994-01-18 The United States Of America As Represented By The Department Of Health And Human Services 2-substituted adenosines and 2-substituted adenosine 5'-carboxamides
DE69123974T2 (de) 1990-09-25 1997-05-07 Rhone-Poulenc Rorer International (Holdings) Inc., Greenville, Del. Verbindungen welche antihypertensive und antiischemische eigenschaften besitzen
CA2100863A1 (en) 1991-01-23 1992-07-24 David A. Bullough Adenosine kinase inhibitors
GB9127376D0 (en) 1991-12-24 1992-02-19 Wellcome Found Amidino derivatives
FR2685918B1 (fr) 1992-01-08 1995-06-23 Union Pharma Scient Appl Nouveaux derives de l'adenosine, leurs procedes de preparation, compositions pharmaceutiques les contenant.
FR2687678B1 (fr) 1992-01-31 1995-03-31 Union Pharma Scient Appl Nouveaux derives de l'adenosine, leurs procedes de preparation, compositions pharmaceutiques les contenant.
NZ251092A (en) 1992-04-02 1996-12-20 Smithkline Beecham Corp 4-cyano-cyclohexane derivatives; medicaments; used in treating asthma
US5424297A (en) 1992-04-27 1995-06-13 University Of Virginia Alumni Patents Foundation Adenosine dextran conjugates
AU4772493A (en) 1992-07-15 1994-02-14 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Sulfo-derivatives of adenosine
GB9301000D0 (en) 1993-01-20 1993-03-10 Glaxo Group Ltd Chemical compounds
CA2154681A1 (en) 1993-02-03 1994-08-18 Mark David Erion Adenosine kinase inhibitors comprising lyxofuranosyl derivatives
IL108523A0 (en) 1993-02-03 1994-05-30 Gensia Inc Pharmaceutical compositions containing adenosine kinase inhibitors for preventing or treating conditions involving inflammatory responses and pain
ATE206432T1 (de) 1993-07-13 2001-10-15 Nasa A3 -adenosin -rezeptor agonisten
US5446046A (en) 1993-10-28 1995-08-29 University Of Florida Research Foundation A1 adenosine receptor agonists and antagonists as diuretics
WO1995018817A1 (fr) 1994-01-07 1995-07-13 Laboratoires Upsa Nouveaux derives de l'adenosine, leurs procedes de preparation, compositions pharmaceutiques les contenant
CA2192668A1 (en) 1994-06-15 1995-12-21 Harold Francis Hodson Amidino sulfone derivatives for use as inos inhibitors claims
GB9414208D0 (en) 1994-07-14 1994-08-31 Glaxo Group Ltd Compounds
GB9414193D0 (en) 1994-07-14 1994-08-31 Glaxo Group Ltd Compounds
WO1996036729A1 (en) 1995-05-18 1996-11-21 Coulter International Corp. An assay reagent and a method of making and using the assay reagent
US6403599B1 (en) 1995-11-08 2002-06-11 Pfizer Inc Corticotropin releasing factor antagonists
US5789589A (en) 1996-04-22 1998-08-04 Drug Innovation & Design, Inc. Guanine analog phosphates
AU3255097A (en) 1996-07-05 1998-02-02 Novo Nordisk A/S Novel (n)-alkoxyadenine derivatives acting as cytokine inhibitors
UA51716C2 (uk) 1996-07-08 2002-12-16 Авентіс Фармасьютікалз Продактс Інк. Сполуки, що мають гіпотензивну, кардіопротекторну, анти-ішемічну та антиліполітичну властивості, фармацевтична композиція та способи лікування
AU4377397A (en) 1996-10-14 1998-05-11 Novo Nordisk A/S Novel therapeutically active adenosine derivatives
TW528755B (en) 1996-12-24 2003-04-21 Glaxo Group Ltd 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
AU5312198A (en) 1997-01-06 1998-08-03 Klaus Trier Aps Screening method
MY117948A (en) 1997-01-13 2004-08-30 Glaxo Group Ltd Nitride oxide synthase inhibitors.
DE19723722A1 (de) 1997-05-30 1998-12-10 Schering Ag Nichtsteroidale Gestagene
WO1999016766A1 (fr) 1997-10-01 1999-04-08 Kyowa Hakko Kogyo Co., Ltd. Derives de benzodioxole
YU44900A (sh) 1998-01-31 2003-01-31 Glaxo Group Limited Derivati 2-(purin-9-il)tetrahidrofuran-3,4-diola
US6506766B1 (en) 1998-02-13 2003-01-14 Abbott Laboratories Glucocortiocoid-selective antinflammatory agents
CO4990969A1 (es) 1998-02-14 2000-12-26 Glaxo Group Ltd Derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol
ATE270278T1 (de) 1998-03-14 2004-07-15 Altana Pharma Ag Phthalazinone pde iii/iv hemmer
GB9811599D0 (en) 1998-05-30 1998-07-29 Glaxo Group Ltd Nitric oxide synthase inhibitors
ID29609A (id) 1998-06-23 2001-09-06 Glaxo Group Ltd Turunan 2-(purin-9-il)-tetrahidrofuran-3,4-diol
GB9813540D0 (en) 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
GB9813565D0 (en) 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
AR028986A1 (es) 1999-02-23 2003-06-04 Smithkline Beecham Corp USO DE UN INHIBIDOR DE PDE4 EN LA FABRICACIoN DE UNA PREPARACIoN DE LIBERACIoN CONTROLADA; FORMULACION DE LIBERACION CONTROLADA PARA EL TRATAMIENTO DE COPD, UN PROCEDIMIENTO PARA SU PREPARACIoN Y COMPOSICIoN FARMACÉUTICA
CA2371273A1 (en) 1999-05-04 2000-11-09 Andrew Fensome Tetracyclic progesterone receptor modulator compounds and methods
US6841549B1 (en) 1999-07-02 2005-01-11 Eisai Co., Ltd. Condensed imidazole compounds and a therapeutic agent for diabetes mellitus
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
US6263209B1 (en) 1999-07-28 2001-07-17 Motorola, Inc. Method and apparatus in a wireless communication system for creating a learning function
CO5180649A1 (es) 1999-09-01 2002-07-30 Abbott Lab Antagonistas de los receptores de los glucocorticoides para el tratamiento de la diabetes para el tratamiento de la diabetes
US6803457B1 (en) 1999-09-30 2004-10-12 Pfizer, Inc. Compounds for the treatment of ischemia
OA11558A (en) 1999-12-08 2004-06-03 Advanced Medicine Inc Beta 2-adrenergic receptor agonists.
AP2002002589A0 (en) 2000-01-31 2002-09-30 Pfizer Prod Inc Nicotinamide benzofused-heterocyclyl derivatives useful as selective inhibitors of PDE4 isozymes.
DZ3406A1 (de) 2000-01-31 2001-08-09 Pfizer Prod Inc
US7585847B2 (en) 2000-02-03 2009-09-08 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for the treatment of asthma and allergy
US6710086B1 (en) 2000-02-25 2004-03-23 Medinox, Inc. Protected forms of pharmacologically active agents and uses therefor
US6753322B2 (en) 2000-06-06 2004-06-22 Pfizer Inc 2-aminocarbonyl-9H-purine derivatives
US6921753B2 (en) 2000-06-27 2005-07-26 Pfizer Inc Purine derivatives
GB0015727D0 (en) 2000-06-27 2000-08-16 Pfizer Ltd Purine derivatives
GB0016002D0 (en) 2000-06-29 2000-08-23 Glaxo Group Ltd Novel process for preparing crystalline particles
CZ20031195A3 (cs) 2000-09-29 2003-09-17 Glaxo Group Limited Morfolinacetamidové deriváty
AU2002210761A1 (en) 2000-11-03 2002-05-15 Glaxo Group Limited Method of determining susceptibility to diseases
GB0028383D0 (en) 2000-11-21 2001-01-03 Novartis Ag Organic compounds
GB0031179D0 (en) 2000-12-21 2001-01-31 Glaxo Group Ltd Nitric oxide synthase inhibitors
DE10064997A1 (de) 2000-12-23 2002-06-27 Merck Patent Gmbh Benzoylpyridazine
US6484903B2 (en) 2001-01-09 2002-11-26 Riverwood International Corporation Carton with an improved dispensing feature in combination with a unique handle
IL156704A0 (en) 2001-01-16 2004-01-04 Can Fite Biopharma Ltd Use of an adenosine a3 receptor agonist for inhibition of viral replication
US7250518B2 (en) 2001-01-31 2007-07-31 Pfizer Inc. Nicotinamide acids, amides, and their mimetics active as inhibitors of PDE4 isozymes
EP1229034B1 (de) 2001-01-31 2005-04-13 Pfizer Products Inc. Nikotinsäureamid-Derivate und ihre Mimetika als Inhibitoren von PDE4-Isozyms
GB0103630D0 (en) 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds
GB0104555D0 (en) 2001-02-23 2001-04-11 Glaxo Group Ltd New Therapeutic method
GB2372742A (en) 2001-03-03 2002-09-04 Univ Leiden C2,5'-Disubstituted and N6,C2,5'-trisubstituted adenosine derivatives and their different uses
JP2004526720A (ja) 2001-03-08 2004-09-02 グラクソ　グループ　リミテッド βアドレナリン受容体のアゴニスト
WO2002072067A2 (en) 2001-03-12 2002-09-19 Glaxo Group Limited Pharmaceutical aerosol formulation
JP4143413B2 (ja) 2001-03-22 2008-09-03 グラクソ グループ リミテッド β２−アドレナリン受容体アゴニストとしてのホルムアニリド誘導体
ES2231681T3 (es) 2001-03-30 2005-05-16 Pfizer Products Inc. Inhibidores de piridazinona de la aldosa reductasa.
US20040204481A1 (en) 2001-04-12 2004-10-14 Pnina Fishman Activation of natural killer cells by adenosine A3 receptor agonists
US6903109B2 (en) 2001-04-18 2005-06-07 Ortho-Muniel Pharmaceutical, Inc. Arylindenopyridines and related therapeutic and prophylactic methods
GB0120124D0 (en) 2001-05-04 2001-10-10 Aventis Pharm Prod Inc Effect of timing and duration of administration of amp 579 on reperfusion injury in rabbit heart
SK14302003A3 (sk) 2001-05-25 2004-08-03 Kombinácia agonistu adenozín A2a receptora a anticholinergického činidla na ošetrovanie obštrukčných chorôb dýchacích ciest
US20030013675A1 (en) 2001-05-25 2003-01-16 Boehringer Ingelheim Pharma Kg Combination of an adenosine A2A-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways and other inflammatory diseases
US7262176B2 (en) 2001-08-08 2007-08-28 Cv Therapeutics, Inc. Adenosine A3 receptor agonists
US20030078232A1 (en) 2001-08-08 2003-04-24 Elfatih Elzein Adenosine receptor A3 agonists
US7361787B2 (en) 2001-09-14 2008-04-22 Glaxo Group Limited Phenethanolamine derivatives for treatment of respiratory diseases
JP4514452B2 (ja) 2001-10-01 2010-07-28 ユニバーシティ オブ バージニア パテント ファウンデーション Ａ２ａアゴニスト活性を有する２−プロピルアデノシン・アナログおよびその組成物
CN1578665A (zh) 2001-10-31 2005-02-09 默克专利股份公司 4型磷酸二脂酶抑制剂及其应用
PL369074A1 (en) 2001-11-02 2005-04-18 Aventis Pharmaceuticals Inc. Pharmaceutical composition comprising an adenosine a1/a2 agonist and a sodium hydrogen exchanger inhibitor
BR0213683A (pt) 2001-11-05 2004-10-26 Merck Patent Gmbh Hidrazono-malonitrilas
US6653323B2 (en) 2001-11-13 2003-11-25 Theravance, Inc. Aryl aniline β2 adrenergic receptor agonists
US6911453B2 (en) 2001-12-05 2005-06-28 Aventis Pharma Deutschland Gmbh Substituted 4-phenyltetrahydroisoquinolinium, process for their preparation, their use as a medicament, and medicament containing them
GB0129273D0 (en) 2001-12-06 2002-01-23 Pfizer Ltd Crystalline drug form
US6703405B2 (en) 2001-12-22 2004-03-09 Aventis Pharma Deutschland Gmbh Substituted 4-phenyltetrahydroisoquinolinium salts, process for their preparation, their use as a medicament, and medicament containing them
DE10163991A1 (de) 2001-12-24 2003-07-03 Merck Patent Gmbh Pyrrolo-pyrimidine
ES2276038T3 (es) 2002-01-14 2007-06-16 Boehringer Ingelheim Pharmaceuticals Inc. Mimeticos de glucocorticoides, metodos para su obtencion, formulaciones farmaceuticas que los contienen y usos de los mismos.
WO2003062256A1 (en) 2002-01-17 2003-07-31 Ribapharm Inc. 2'-beta-modified-6-substituted adenosine analogs and their use as antiviral agents
AU2003214879B2 (en) 2002-01-22 2008-02-07 The Regents Of The University Of California Non-steroidal ligands for the glucocorticoid receptor, compositions and uses thereof
EP1469864A1 (de) 2002-01-25 2004-10-27 Muscagen Limited Verbindungen verwendbar als adenosin-a3-rezeptor-agoniste
US6756392B2 (en) 2002-02-11 2004-06-29 Pfizer Inc Nicotinamide derivatives useful as PDE4 inhibitors
OA12768A (en) 2002-02-11 2006-07-04 Pfizer Nicotinamide derivatives useful as PDE4 inhibitors.
GB0204719D0 (en) 2002-02-28 2002-04-17 Glaxo Group Ltd Medicinal compounds
NZ535314A (en) 2002-03-18 2007-08-31 Schering Corp Combination treatments for chemokine-mediated diseases
CA2477592A1 (en) 2002-03-18 2003-09-25 Yamanouchi Pharmaceutical Co., Ltd. Powdery medicinal compositions for inhalation and process for producing the same
GB0206657D0 (en) 2002-03-21 2002-05-01 Glaxo Group Ltd Novel intermediate and process
GB0206655D0 (en) * 2002-03-21 2002-05-01 Glaxo Group Ltd Novel process
AU2003230700A1 (en) 2002-03-26 2003-10-13 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
EP1490062B1 (de) 2002-03-26 2007-12-19 Boehringer Ingelheim Pharmaceuticals Inc. Glucocorticoid-mimetika, deren herstellung, pharmazeutische zusammensetzungen und verwendung
DE10215316C1 (de) 2002-04-02 2003-12-18 Schering Ag Chinolin- und Isochinolin-Derivate, ein pharmazeutisches Mittel und ihre Verwendung als Entzündungshemmer
EP1496892B1 (de) 2002-04-11 2011-01-26 Merck Sharp & Dohme Corp. 1h-benzo(f)indazol-5-yl-derivate als selektive glucocorticoid-rezeptor-modulatoren
GB0208608D0 (en) 2002-04-13 2002-05-22 Glaxo Group Ltd Composition
US20040127510A1 (en) 2002-04-16 2004-07-01 Heintzelman Geoffrey R. Arylindenopyridines and arylindenopyrimidines and related therapeutic and prophylactic methods
EP1497261B1 (de) 2002-04-25 2007-12-19 Glaxo Group Limited Phenethanolaminderivate
AU2003251303A1 (en) 2002-05-21 2003-12-12 Glaxo Group Limited Pharmaceutical products and methods of manufacture
US7186864B2 (en) 2002-05-29 2007-03-06 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
US7074806B2 (en) 2002-06-06 2006-07-11 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
CA2491994C (en) 2002-07-08 2013-11-05 Pfizer Products Inc. Modulators of the glucocorticoid receptor
US7442554B2 (en) 2002-07-18 2008-10-28 Bristol-Myers Squibb Company Compositions and methods involving glucocorticoid receptor site II
US6995181B2 (en) 2002-07-18 2006-02-07 Bristol-Myers Squibb Co. Modulators of the glucocorticoid receptor and method
GB0217225D0 (en) 2002-07-25 2002-09-04 Glaxo Group Ltd Medicinal compounds
AU2003259747A1 (en) 2002-08-21 2004-03-11 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted hihydroquinolines as glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
US20050113302A1 (en) 2002-08-29 2005-05-26 Thompson John F. A3 receptor-mediated cardioprotective proteins and therapeutic and diagnostic methods of use
GB0220730D0 (en) 2002-09-06 2002-10-16 Glaxo Group Ltd Medicinal compounds
US7112572B2 (en) 2002-09-09 2006-09-26 Trigen Limited Multivalent metal salts of boronic acids
CN100553639C (zh) 2002-09-09 2009-10-28 特里根有限公司 用于治疗血栓形成的硼酸多价金属盐
WO2004022573A2 (en) 2002-09-09 2004-03-18 Cv Therapeutics, Inc. Adenosine a3 receptor agonists
BR0314392A (pt) 2002-09-16 2005-07-12 Glaxo Group Ltd Composto ou um sal do mesmo, composição farmacêutica, uso de um composto, método de tratamento e/ou profilaxia de uma doença inflamatória e/ou alérgica ou deficiência cognitiva em um mamìfero, e, combinação
DK1545587T3 (da) 2002-09-16 2011-05-09 Agennix Inc Lactoferrinsammensætninger og fremgangsmåder til behandling af diabetiske sår
US20040229780A1 (en) 2002-09-20 2004-11-18 Olivera Baldomero M. KappaM-conopeptides as organ protectants
US20050245588A1 (en) 2002-09-20 2005-11-03 Amjad Ali Octahydro-2-h-naphtho[1,2-f]indole-4-carboxamide derivatives as selective glucocorticoid receptor modulators
AU2003270752A1 (en) 2002-09-27 2004-04-19 King Pharmaceuticals Research And Development, Inc. A method to demonstrate the efficacy of pharmacological stress agent
AU2003277044A1 (en) 2002-09-30 2004-04-23 The Trustees Of Boston University Method of treating cancer using adenosine and its analogs
AU2003288922A1 (en) 2002-10-09 2004-05-04 Pharmacopeia, Inc. Thiadiazoledioxides and thiadiazoleoxides as cxc- and cc-chemokine receptor ligands
EP1556034B1 (de) 2002-10-11 2008-04-16 Pfizer Limited Indolderivate als beta-2 agonisten
EP1407769A1 (de) 2002-10-11 2004-04-14 Pfizer Limited Indolderivate als beta-2 Agonisten
US6844362B2 (en) 2002-10-11 2005-01-18 Pfizer Inc Indole derivatives useful for the treatment of diseases
JP2006506373A (ja) 2002-10-22 2006-02-23 グラクソ　グループ　リミテッド 医薬アリールエタノールアミン化合物
EP1578758A4 (de) 2002-10-25 2009-09-30 Us Gov Health & Human Serv Purinnukleoside
AR041724A1 (es) 2002-10-28 2005-05-26 Glaxo Group Ltd Compuestos derivados de fenetanolamina y su utilizacion en composiciones farmaceuticas
GB0225030D0 (en) 2002-10-28 2002-12-04 Glaxo Group Ltd Medicinal compounds
GB0225540D0 (en) 2002-11-01 2002-12-11 Glaxo Group Ltd Medicinal compounds
GB0225535D0 (en) 2002-11-01 2002-12-11 Glaxo Group Ltd Medicinal compounds
AU2003293405A1 (en) 2002-12-03 2004-06-23 Vela Pharmaceuticals, Inc. Pharmaceutical composition of 1-(3,4-dimethoxyphenyl)-4-methyl-5-ethyl-7-methoxy-8-hydroxy-5h-2,3-benzodiazepine and uses thereof
GB0228723D0 (en) 2002-12-09 2003-01-15 Cambridge Biotechnology Ltd Treatment of pain
CA2451267A1 (en) 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
CA2512819A1 (en) 2003-01-14 2004-07-29 Altana Pharma Ag Pde4 inhibitors for the treatment of neoplasms of lymphoid cells
US20040166574A1 (en) 2003-02-25 2004-08-26 Antonius John I. Microorganism
US20040175382A1 (en) 2003-03-06 2004-09-09 Schafer Peter H. Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system
GB0305149D0 (en) 2003-03-07 2003-04-09 Cambridge Biotechnology Ltd Compounds for the treatment of pain
GB0305153D0 (en) 2003-03-07 2003-04-09 Cambridge Biotechnology Ltd Identification of therapeutic compounds
GB0305150D0 (en) 2003-03-07 2003-04-09 Cambridge Biotechnology Ltd Use of therapeutic compounds
EP1460064A1 (de) 2003-03-14 2004-09-22 Pfizer Limited Indole-2-carboxamide als beta-2 Agonisten
US20040184995A1 (en) 2003-03-17 2004-09-23 Yamanouchi Pharmaceutical Co., Ltd. Novel dry powder inhalation for lung-delivery and manufacturing method thereof
US20040258740A1 (en) 2003-04-10 2004-12-23 Nene Labs Transdermal delivery composition
BRPI0409492A (pt) 2003-04-18 2006-05-02 Pharmacia & Up John Company Ll terapias de combinação
EP1477167A1 (de) 2003-05-15 2004-11-17 Pfizer Limited [(2-hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)-ethylamino)-propyl] phenyl derivative als beta2 agonist
US7268147B2 (en) 2003-05-15 2007-09-11 Pfizer Inc Compounds useful for the treatment of diseases
TWI328009B (en) 2003-05-21 2010-08-01 Glaxo Group Ltd Quinoline derivatives as phosphodiesterase inhibitors
US7375100B2 (en) 2003-06-04 2008-05-20 Pfizer Inc 2-amino-pyridine derivatives useful for the treatment of diseases
ATE384697T1 (de) 2003-06-04 2008-02-15 Pfizer 2-amino-pyridin-derivate als beta-2 adrenoreceptor agonisten
GB0312832D0 (en) 2003-06-04 2003-07-09 Pfizer Ltd 2-amino-pyridine derivatives useful for the treatment of diseases
US7067541B2 (en) 2003-06-04 2006-06-27 Pfizer Inc 2-amino-pyridine derivatives useful for the treatment of diseases
WO2004110454A1 (ja) 2003-06-13 2004-12-23 Ishihara Sangyo Kaisha, Ltd. アデノシンＡ2ａ受容体アゴニストの投与が必要な疾患を治療又は予防するための組成物
US6974862B2 (en) 2003-06-20 2005-12-13 Kensey Nash Corporation High density fibrous polymers suitable for implant
GB0317472D0 (en) 2003-07-25 2003-08-27 Pfizer Ltd Nicotinamide derivatives useful as PDE4 inhibitors
US7153870B2 (en) 2003-07-25 2006-12-26 Pfizer Inc. Nicotinamide derivatives useful as PDE4 inhibitors
GB0317471D0 (en) 2003-07-25 2003-08-27 Pfizer Ltd Novel compounds
GB0317516D0 (en) 2003-07-25 2003-08-27 Pfizer Ltd Nicotinamide derivatives useful as PDE4 inhibitors
US20050020587A1 (en) 2003-07-25 2005-01-27 Pfizer Inc Nicotinamide derivatives useful as PDE4 inhibitors
GB0317498D0 (en) 2003-07-25 2003-08-27 Pfizer Ltd Compounds
GB0317482D0 (en) 2003-07-25 2003-08-27 Pfizer Ltd Nicotinamide derivatives useful as pde4 inhibitors
GB0317509D0 (en) 2003-07-25 2003-08-27 Pfizer Ltd Nicotinamide derivatives useful as PDE4 inhibitors
GB0317484D0 (en) 2003-07-25 2003-08-27 Pfizer Ltd Nicotinamide derivatives useful as pde4 inhibitors
US7132435B2 (en) 2003-07-25 2006-11-07 Pfizer Inc. Compounds
GB0317951D0 (en) 2003-07-31 2003-09-03 Trigen Ltd Compounds
AU2004274475B2 (en) 2003-09-18 2009-08-06 King Pharmaceuticals Research & Development, Inc. Novel adenosine A3 receptor agonists

Also Published As

Publication number Publication date
MA28611B1 (fr) 2007-05-02
EP1756120A1 (de) 2007-02-28
US20080132526A1 (en) 2008-06-05
JP2008500378A (ja) 2008-01-10
WO2005116037A1 (en) 2005-12-08
ES2383604T3 (es) 2012-06-22
MXPA06013627A (es) 2007-02-28
AU2005247601A1 (en) 2005-12-08
BRPI0511424A (pt) 2007-12-11
AR049384A1 (es) 2006-07-26
PE20060272A1 (es) 2006-05-22
IL179009A0 (en) 2007-03-08
EP1756120B1 (de) 2012-05-02
NO20065757L (no) 2006-12-13
US7737126B2 (en) 2010-06-15
RU2006141276A (ru) 2008-06-27
JP5007225B2 (ja) 2012-08-22
CA2566863A1 (en) 2005-12-08

Similar Documents

Publication Publication Date Title
IS8578A (is) 3- karbamoýl - 2- pýridón afleiður
NL1031741A1 (nl) Purinederivaten.
ATE553079T1 (de) Heteroarylphenylharnstoffderivat
EP1778298A4 (de) Lipoprotein-nanoplattformen
DK1725553T3 (da) Tetrahydropyridoindolderivater
DE602004029102D1 (de) Spiegelwinkeleinstellvorrichtung
ATE383361T1 (de) Pyrrazolopyrimidinderivate
ATE540935T1 (de) Chinazolinderivate
MA28611B1 (fr) Derive de purine
DE602006010581D1 (de) 4-phenyl-6-substituierte pyrimidin-2-carbonitrilderivate
ATE485294T1 (de) Azaindol-2-carboxamid-derivate
ATE527255T1 (de) Aryl-isoxazol-4-yl-imidazol-derivate
DK1971588T3 (da) Tiglien-3-onderivater
ATE392425T1 (de) Thiazolyl-dihydro-indazole
DE602004017368D1 (de) Verschliessmaschinenkopf
ATE417830T1 (de) Sulfonylbenzimidazolderivate
DE602005007966D1 (de) Reifenabdrückvorrichtung
DE502005004843D1 (de) Einspritzventil
DE502005006395D1 (de) Verschlusskappe
DK1765844T3 (da) Purin-nukleotidderivater
DE502005008587D1 (de) Kugelgelenk
ATE430142T1 (de) Phenylpiperazin-methanon-derivate
DE602005005896D1 (de) Bogenfalzeinrichtung
DE202004017327U1 (de) Fitnessrad
ATE404542T1 (de) 4-phenylpyrimidin-2-carbonitrilderivate